Pricing Log in Create free account
Friday 6 November 2026 Export CRSP’s income statement to Excel — free account

CRISPR Therapeutics AG

CRSP Healthcare Biotechnology

CRISPR Therapeutics AG’s revenue for fiscal 2025 (year ended December 2025) was $3.5 million, down 90.6% from fiscal 2024.

Revenue
+1,325.1%
EPS
+1.55%
Free cash flow
−6.36%

Quarter to September 2026, against a year earlier

49.92 1.36 +2.80%
Market cap
$4.7B
P/E
0.0×
Fwd P/E
−11.8×
Dividend yield
—
F-score
2/9
Altman Z
7.04
Beneish M
n/a
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Sold, $m 17.94
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell 1 3 2 9 — 1 — — — 2 5 —
Insider Ownership 6.92%

Capital & Financial Ratios $m

Size
Market Cap 4,710.00
Revenue ttm 25.17
Net income ttm (456.13)
Free cash flow ttm (376.71)
Net debt Q (1,685.61)
Valuation
P/E 0.00
Forward P/E (11.80) (negative: loss-making)
Price / sales 191.85 (above 10: high)
Forward P/S Powerpack
Price / FCF 0.00
Price / book 2.93
Financial health
Current ratio Q 16.21 (at or above 1.5: strong)
Debt / equity Q 0.36 (at or below 0.5: strong)
Interest coverage Q 25,310.00
Growth
Revenue growth Q +1,325.08% (above 0%: growing)
Operating income growth Q +1.53% (above 0%: growing)
EPS, this year +30.40% (at or above 15%: strong)
EPS, next year A +21.15% (at or above 15%: strong)
Revenue, next year A +1,052.14% (at or above 10%: strong)
EPS, past 5 yrs —
EPS, next 5 yrs A +32.43% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 125×, against a ten-year median of 45.0×; over the ten years it ranged from −19.0× in 2017 to 12,917× in 2021.
P/S against its own 10 years 71.32%
10-year low 10-year high
P/B against its own 10 years 48.10%
10-year low 10-year high
EV/Sales against its own 10 years 70.19%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 1,694 1,904 1,976 2,273
Receivables 200 25 — —
Inventory — — — —
Other — — — —
1,908 1,937 1,986 2,285
2023 2024 2025 Q'26
Payables 38 15 11 21
ST’ Debt — — — —
Other 5 10 13 17
109 88 149 141

Compound Annual Growth %

10y 5y 3y
Sales 30.40% 37.31% 43.09%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 0.00% 2.92% 0.82%

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate −1.10 Actual −0.94

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q3 FY25 −1.32 −1.17 Beat by 0.15
Q4 FY25 −1.15 −1.37 Miss by 0.22
Q1 FY26 −1.14 −1.28 Miss by 0.14
Q2 FY26 −1.10 −0.94 Beat by 0.16
Q3 FY26 −1.06 — Reports 9 November 2026

EPS $

Mar Jun Sep Dec Year
’26 (1.28) (0.94) (1.15) — —
’25 (1.58) (2.40) (1.17) (1.37) (6.47)
’24 (1.43) (1.49) (1.01) (0.44) (4.34)
’23 (0.67) (0.98) (1.41) 1.10 (1.94)
’22 (2.32) (2.40) (2.24) (1.41) (8.36)
’21 (1.51) 9.44 (1.67) (1.84) 4.70
’20 (1.15) (1.30) (1.32) (1.50) (5.29)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 1 10 13 — —
’25 1 1 1 1 4
’24 1 1 1 36 37
’23 100 70 — 201 371
’22 1 0 0 0 1
’21 1 901 1 13 915
’20 0 0 0 0 1
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (109) (83) (90) — —
’25 (54) (114) (85) (93) (345)
’24 110 (96) (107) (50) (143)
’23 9 (133) (40) (96) (260)
’22 (135) (142) (105) (113) (496)
’21 (101) 807 (81) (86) 539
’20 (52) (29) (76) (81) (238)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (109) (84) (90) — —
’25 (54) (114) (85) (93) (346)
’24 109 (96) (107) (50) (145)
’23 6 (137) (42) (97) (270)
’22 (151) (152) (111) (120) (533)
’21 (108) 779 (118) (95) 457
’20 (55) (33) (81) (87) (257)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.9
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 5 41 3 290 1 915 1 371 37 4 25 (4.2%) 40 154 566 +444.2%
Gross margin, % 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 0.0 pt
EBT (23) (67) (164) 67 (348) 380 (650) (151) (363) (578) (454) +43.3%
EBT margin, % (439.93) (162.47) (5,263.38) 23.24 (48,408.34) 41.48 (54,298.83) (40.60) (971.93) (16,466.24) (1,802.19) (16,026.3) pt
Net income (23) (68) (165) 67 (349) 378 (650) (154) (366) (582) (456) +43.0%
Per share, $
Per share, $ Revenue 0.42 1.02 0.07 5.32 0.01 12.05 0.02 4.69 0.44 0.04 0.26 (23.2%)
Earnings (1.89) (1.71) (3.44) 1.23 (5.29) 4.97 (8.36) (1.94) (4.34) (6.47) (4.74) +14.7%
Cash flow (4.51) (1.75) (2.01) 1.04 (3.61) 7.10 (6.38) (3.29) (1.69) (3.84) (3.87) (1.8%)
Capex (0.25) (0.20) (0.06) (0.12) (0.28) (1.08) (0.48) (0.12) (0.02) (0.01) (0.02) (29.8%)
Free cash flow (4.76) (1.94) (2.06) 0.92 (3.89) 6.02 (6.85) (3.41) (1.71) (3.85) (3.89) (2.3%)
Book value 19.00 4.69 8.18 17.27 25.23 31.59 24.12 23.77 22.90 21.37 17.04 +1.3%
Shares, m 12 40 48 54 66 76 78 79 84 90 95 +24.8%
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 54.87 0.00 15.19 0.00 0.00 0.00 0.00 0.00 7.0
P/S 53.41 24.59 438.65 11.44 14,043.96 6.29 2,660.79 14.10 88.98 1,343.49 191.85 1,868.6
P/B 1.18 5.37 3.49 3.53 6.07 2.40 1.70 2.78 1.72 2.45 2.93 3.1
EV/Sales (7.69) 18.74 292.47 8.33 11,762.55 3.92 1,335.82 10.15 44.05 845.25 124.89 1,431.4
EV/FCF 0.68 (9.86) (9.23) 48.27 (32.94) 7.85 (3.00) (13.96) (11.36) (8.58) (8.34) (3.2)
Cash, $m
Cash, $m Operating cash flow (55) (70) (96) 57 (238) 539 (496) (260) (143) (345) (375) +22.6%
Capex (3) (8) (3) (7) (18) (82) (37) (9) (2) (1) (2) (12.4%)
Free cash flow (58) (78) (99) 50 (257) 457 (533) (270) (145) (346) (377) +21.9%
Balance, $m
Balance, $m Working capital 298 234 439 930 1,622 2,298 1,732 1,799 1,849 1,837 2,144 +22.4%
Net debt (316) (240) (457) (944) (1,690) (2,379) (1,815) (1,694) (1,904) (1,976) (1,686) +22.6%
Shareholders’ equity 233 188 392 939 1,664 2,399 1,875 1,883 1,932 1,922 1,648 +26.4%
Returns, %
Returns, % ROA (9.19) (22.18) (43.40) 8.59 (24.10) 16.49 (26.03) (6.87) (16.38) (25.81) (19.00) (16.6) pt
ROIC 0.00 0.00 0.00 0.00 0.00 1,148.27 (699.33) (73.55) (1,032.08) 0.00 0.00 0.0 pt
ROE (22.75) (32.50) (56.89) 10.04 (26.80) 18.59 (30.42) (8.17) (19.20) (30.18) (25.60) (7.4) pt
People
People Employees 93 127 188 304 410 473 458 407 393 0 — n/m
Revenue/emp, $m 0.06 0.32 0.02 0.95 0.00 1.93 0.00 0.91 0.09 0.00 — n/m
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 6 Nov 2026

CRISPR Therapeutics AG vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
MANE Veradermics Incorporated $5.4B — (loss-making) — — n/m −8.81% (below 0%: shrinking) — 0.00% Compare
COGT Cogent Biosciences, Inc. $5.1B — (loss-making) — (loss-making) −69.41% (below 0%: shrinking) n/m −42.01% (below 0%: shrinking) 0.00% 0.00% Compare
CRSP CRISPR Therapeutics AG $4.7B — (loss-making) — (loss-making) +1,325.08% (above 0%: growing) n/m −6.36% (below 0%: shrinking) 100.00% (1,026.48%)
TVTX Travere Therapeutics, Inc. $4.7B — (loss-making) — (loss-making) +36.22% (above 0%: growing) n/m +6,379.75% (above 0%: growing) 98.72% (30.33%) Compare
DNTH Dianthus Therapeutics, Inc. $4.6B — (loss-making) — (loss-making) +205.56% (above 0%: growing) n/m −65.91% (below 0%: shrinking) 100.00% (4,832.40%) Compare
ERAS Erasca, Inc. $4.6B — (loss-making) — — n/m −4.67% (below 0%: shrinking) 0.00% 0.00% Compare
LEGN Legend Biotech Corporation Sponsored ADR $4.4B — (loss-making) — (loss-making) +51.90% (above 0%: growing) n/m −26.79% (below 0%: shrinking) 64.54% 14.37% Compare
EWTX Edgewise Therapeutics, Inc. $4.2B 4.9× — — n/m −30.24% (below 0%: shrinking) 0.00% 0.00% Compare
DFTX Definium Therapeutics, Inc. $4.1B — (loss-making) — — n/m −78.31% (below 0%: shrinking) 0.00% 0.00% Compare
Median of peers $4.6B — — +44.06% — −28.51% 0.00% 0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 21 April 2026

Chief executive’s pay

Year Total pay Actually paid $100 invested
2025 7.68m 21.97m 34.25
2024 33.18m 10.02m 64.63
2023 12.32m 24.81m 102.78
2022 20.73m 1.73m 66.74
2021 17.04m (27.37m) 124.42

Ownership

Directors and executive officers, together 5.20%
ARK Investment Management LLC 10.20%
BlackRock, Inc. 6.20%
Orbis Investment Management LTD 6.20%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

CRISPR Therapeutics AG (CRSP) Latest News

3 Nov

Impact 3 · · MT Newswires
Impact 3 · · Zacks

2 Nov

Impact 3 · · The Motley Fool
Impact 3 · · GlobeNewswire

27 Oct

Impact 3 · · Zacks

25 Oct

Impact 4 · · Simply Wall St.
Impact 4 · · Simply Wall St.

24 Oct

Impact 4 · · The Motley Fool

23 Oct

Impact 4 · · Zacks
Impact 3 · · Barchart

22 Oct

Impact 3 · · Zacks

19 Oct

Impact 3 · · GlobeNewswire

18 Oct

Impact 4 · · The Motley Fool
Impact 4 · · The Motley Fool

16 Oct

Impact 3 · · Zacks

14 Oct

Impact 3 · · Simply Wall St.
Impact 3 · · Simply Wall St.

12 Oct

Impact 3 · · Zacks
Impact 3 · · Zacks

9 Oct

Impact 4 · · The Motley Fool

8 Oct

Impact 3 · · GlobeNewswire

6 Oct

Impact 3 · · Zacks

5 Oct

Impact 3 · · Zacks

2 Oct

Impact 3 · · GlobeNewswire

30 Sep

Impact 3 · · Barchart

29 Sep

Impact 3 · · Zacks
Impact 3 · · The Motley Fool

25 Sep

Impact 3 · · Zacks

24 Sep

Impact 4 · · The Motley Fool

23 Sep

Impact 3 ·

CRSP metrics, ten years each

stockrow.com/CRSP · Data as of Nov 6, 2026 · For information only; not investment advice. · © 2026 stockrow.com